Literature DB >> 9235916

p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes.

D Chantry1, A Vojtek, A Kashishian, D A Holtzman, C Wood, P W Gray, J A Cooper, M F Hoekstra.   

Abstract

We have identified a novel p110 isoform of phosphatidylinositol 3-kinase from human leukocytes that we have termed p110delta. In addition, we have independently isolated p110delta from a mouse embryo library on the basis of its ability to interact with Ha-RasV12 in the yeast two-hybrid system. This unique isoform contains all of the conserved structural features characteristic of the p110 family. Recombinant p110delta phosphorylates phosphatidylinositol and coimmunoprecipitates with p85. However, in contrast to previously described p110 subunits, p110delta is expressed in a tissue-restricted fashion; it is expressed at high levels in lymphocytes and lymphoid tissues and may therefore play a role in phosphatidylinositol 3-kinase-mediated signaling in the immune system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9235916     DOI: 10.1074/jbc.272.31.19236

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  94 in total

1.  A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling.

Authors:  M L Boytim; P Lilly; K Drouvalakis; S C Lyu; R Jung; A M Krensky; C Clayberger
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  Novel agents in mantle cell lymphoma.

Authors:  Marcus S Noel; Jonathan W Friedberg; Paul M Barr
Journal:  Best Pract Res Clin Haematol       Date:  2012-04-30       Impact factor: 3.020

Review 3.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

Review 4.  ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.

Authors:  De-xin Kong; Takao Yamori
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

5.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

Review 6.  Molecules in medicine mini-review: isoforms of PI3K in biology and disease.

Authors:  Bart Vanhaesebroeck; Maria A Whitehead; Roberto Piñeiro
Journal:  J Mol Med (Berl)       Date:  2015-12-10       Impact factor: 4.599

7.  High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival.

Authors:  Susanne Fransson; Katarina Ejeskär
Journal:  Med Oncol       Date:  2013-09-12       Impact factor: 3.064

Review 8.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

9.  P110α and P110δ catalytic subunits of PI3 kinase regulate lysophosphatidylcholine-induced TRPC6 externalization.

Authors:  Pinaki Chaudhuri; Andrew H Smith; Priya Putta; Linda M Graham; Michael A Rosenbaum
Journal:  Am J Physiol Cell Physiol       Date:  2021-02-24       Impact factor: 4.249

10.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.